0000078003-23-000118.txt : 20231212 0000078003-23-000118.hdr.sgml : 20231212 20231212163524 ACCESSION NUMBER: 0000078003-23-000118 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231207 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231212 DATE AS OF CHANGE: 20231212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 231481667 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20231207.htm PFIZER 8-K DECEMBER 7 2023 pfe-20231207
0000078003false00000780032023-12-072023-12-070000078003us-gaap:CommonStockMember2023-12-072023-12-070000078003pfe:NotesDue20271.000Member2023-12-072023-12-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 7, 2023

PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware1-361913-5315170
(State or other(Commission File(I.R.S. Employer
jurisdiction ofNumber)Identification No.)
incorporation)  
66 Hudson Boulevard East10001-2192
New York, New York (Zip Code)
(Address of principal executive offices)

Registrant’s telephone number, including area code:
(212) 733-2323

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE27New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐






Item 5.02.      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 12, 2023, Pfizer Inc. (“Pfizer” or “the Company”) announced that given the size and geographic scope of Pfizer’s commercial operations and the anticipated close of the acquisition of Seagen Inc. (“Seagen”), the following changes to its commercial operations will become effective on January 1, 2024.

Pfizer will create an end-to-end business organization called Pfizer Oncology Division, which will integrate certain Oncology Commercial and R&D operations from both Pfizer and Seagen and will be led by Dr. Chris Boshoff, who will become Chief Oncology Officer, Executive Vice President, and continue reporting to Dr. Albert Bourla, Chairman and Chief Executive Officer. Pfizer will split its non-oncology commercial organization into two more focused business divisions: the Pfizer U.S. Commercial Division, which will be led by Aamir Malik, who will become Chief U.S. Commercial Officer, Executive Vice President, and continue reporting to Dr. Bourla, and the Pfizer International Commercial Division, which will be led by Alexandre de Germay, who will join Pfizer as Chief International Commercial Officer, Executive Vice President, and will report to Dr. Bourla. Dr. Boshoff and Messrs. Malik and de Germay’s new roles will be effective December 15, 2023.

As a result of this reorganization, the role currently held by Angela Hwang, Chief Commercial Officer, Executive Vice President, is being eliminated and she will cease serving in her current role and as a member of the Company’s Executive Leadership Team effective as of December 15, 2023. Ms. Hwang has agreed to assist with the reorganization and transition of her duties and will serve as Advisor to the Chief Executive Officer continuing until a date to be determined. As a result of the elimination of Ms. Hwang’s role, which the Company determined to be an involuntary termination without cause (due to position elimination and reorganization) under the Executive Severance Plan, she will be entitled to severance benefits under the terms and conditions of the Executive Severance Plan. Severance benefits are subject to Ms. Hwang’s execution and non-revocation of a release of claims in favor of the Company and continued compliance with restrictive covenants and her confidentiality obligations. In addition, due to her age and years of service, Ms. Hwang will also be eligible for retirement benefits under the pension and savings plans and retiree medical plan, as well as retirement treatment for her long-term incentive awards in accordance with their terms. All payments and benefits being provided to Ms. Hwang in connection with her departure are consistent with her existing benefit entitlements.
Item 7.01.     Regulation FD Disclosure.
As previously disclosed, on March 12, 2023, Pfizer entered into an Agreement and Plan of Merger with Seagen, pursuant to which Pfizer will acquire Seagen through a merger (the “Merger”). On December 12, 2023, Pfizer announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired on December 11, 2023. A copy of the press release is attached as Exhibit 99.1 hereto.

Pfizer and Seagen have now received all required regulatory approvals for the closing of the Merger. Pfizer now expects to complete the Merger on December 14, 2023, subject to the satisfaction of other customary closing conditions.

Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Exhibit Description
Exhibit 99.1
104Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

Cautionary Statement Regarding Forward-Looking Statements

This current report on Form 8-K contains forward-looking information about, among other topics, Pfizer’s proposed acquisition of Seagen and changes to Pfizer’s commercial organization, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated


successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of the consummation of the proposed acquisition on the market price of Pfizer’s common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition or Seagen’s business; risks related to the financing of the transaction; the impact of and risks and uncertainties related to internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs, organizational disruption or other unintended consequences; uncertainties regarding the impact of COVID-19; other business effects and uncertainties; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 PFIZER INC.
   
   
 By:/s/ Margaret M. Madden
 Margaret M. Madden
  Senior Vice President and Corporate Secretary
  Chief Governance Counsel
   
Dated: December 12, 2023





 EX-99.1 2 pr121223ex991.htm EX-99.1 Document

Exhibit 99.1
pfizerlogoa.jpg

For Immediate Release
December 12, 2023		Media Contact: PfizerMediaRelations@Pfizer.com
 +1 (212) 733-1226

Investor Contact: IR@Pfizer.com
 +1 (212) 733-4848
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
•Expects to close Seagen acquisition on December 14, 2023
•Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
•Pfizer to host analyst and investor call at 8:30 am EST on Wednesday, December 13, 2023, to discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance

NEW YORK, December 12, 2023—Pfizer Inc. (NYSE: PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer’s pending acquisition of Seagen Inc. (NASDAQ: SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition. Pfizer expects to close the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions.
To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio® (avelumab) in the U.S. to the American Association for Cancer Research (AACR). This unrestricted donation will support AACR in its mission to prevent and cure cancer through research, education, communication, collaboration, science policy, and funding for cancer research.
Changes in Commercial Organization
Pfizer also announces changes in its commercial organization to incorporate Seagen and improve focus, speed and quality of execution. Specifically, Pfizer will create an end-to-end business organization called the Pfizer Oncology Division, which will integrate certain oncology commercial and R&D operations from
1


both companies and will be led by Dr. Chris Boshoff, who will become Chief Oncology Officer, Executive Vice President, and continue reporting to Dr. Albert Bourla, Chairman and Chief Executive Officer. Pfizer will split its non-oncology commercial organization into two more focused business divisions: the Pfizer U.S. Commercial Division, which will be led by Aamir Malik, who will become Chief U.S. Commercial Officer, Executive Vice President, and continue reporting to Dr. Bourla; and the Pfizer International Commercial Division, which will be led by Alexandre de Germay, who will join Pfizer as Chief International Commercial Officer, Executive Vice President, and will report to Dr. Bourla. Biographical information for Alexandre de Germay can be found at https://cdn.pfizer.com/pfizercom/2023-12/ADG-Bio.pdf.
While these three leaders will begin transitioning to their new roles immediately after the completion of the Seagen acquisition, the new organization structure will go into effect January 1, 2024.
After a stellar nearly 27-year career at Pfizer, Angela Hwang, Chief Commercial Officer, and President, Global Biopharmaceuticals Business will be leaving Pfizer. Angela has agreed to stay on as an advisor to help transition the organization into the new model. Under Angela’s leadership, Pfizer introduced an unprecedented number of new medicines and vaccines to patients across the globe.
“The completion of all regulatory reviews in association with the Seagen acquisition supports our belief that this transaction is good for patients in the battle against cancer,” said Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer. “With the anticipated Seagen closing in the coming days, Pfizer has announced changes to the company’s commercial structure designed to maximize the impact of this transaction and enhance our commercial execution across all the company’s therapeutic areas. I also want to thank Angela Hwang and celebrate her vast achievements and the unforgettable legacy she leaves behind. Angela is a purpose-driven leader, and her focus has consistently been on working to bring more breakthroughs to patients around the world.”
Invitation to Public Webcast to Discuss Seagen Acquisition and Provide Full-Year 2024 Financial Guidance
Separately, Pfizer invites investors and the general public to view and listen to a webcast of a live conference call with investment analysts at 8:30 a.m. EST on Wednesday, December 13, 2023. During the call Pfizer will discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance.
To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call.
You can also listen to the conference call by dialing either (800) 456-4352 in the United States and Canada or (785) 424-1086 outside of the United States and Canada. The passcode is 70115.
2


The transcript and webcast replay of the call will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live conference call and will be accessible for at least 90 days.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Disclosure Notice: This press release and the webcast contain or may contain forward-looking information about, among other topics, Pfizer’s proposed acquisition of Seagen, including the anticipated timing of completion of the proposed acquisition; changes to Pfizer’s commercial organization; reorganizations, business plans, strategy and prospects; Pfizer’s anticipated operating and financial performance; Pfizer’s and Seagen’s commercialized and pipeline products and Seagen’s technology platform; and other statements about our business, operations and financial results, including, in each case, their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Pfizer’s common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition or Seagen’s business; risks related to the financing of the transaction; other business effects and uncertainties and the uncertainties inherent in business and financial planning, including the effects of industry, market, business, economic, political or regulatory conditions, risks related to Pfizer’s business and prospects, adverse developments in Pfizer’s markets or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or
3


economies generally; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; uncertainties regarding the commercial success of Pfizer’s and Seagen’s commercialized and pipeline products; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when drug applications may be filed in any jurisdictions for Pfizer’s or Seagen’s pipeline products; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such products will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of such products; uncertainties regarding the impact of COVID-19; competitive developments; uncertainties regarding the impact, success and associated costs of our enterprise-wide cost realignment program; and the impact of and risks and uncertainties related to restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs, organizational disruption or other unintended consequences.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in this release and the webcast speak only as of the date of this release and the original date of the webcast, respectively. Pfizer assumes no obligation to update forward-looking statements contained in this release or the webcast as the result of new information or future events or developments.
All trademarks mentioned are the property of their owners.
# # #
4

 EX-101.SCH 3 pfe-20231207.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 pfe-20231207_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 pfe-20231207_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Information [Line Items] Entity Information [Line Items] Notes Due 2027, 1.000% [Member] Notes Due 2027, 1.000% [Member] Notes Due 2027, 1.000% [Member] Document Period End Date Document Period End Date Common Stock [Member] Common Stock [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer Class of Stock [Domain] Class of Stock [Domain] Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Written Communications Written Communications Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type Amendment Flag Amendment Flag Class of Stock [Axis] Class of Stock [Axis] Entity File Number Entity File Number Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 pfe-20231207_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 pfizerlogoa.jpg begin 644 pfizerlogoa.jpg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v3.23.3
Cover Page
Dec. 07, 2023
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Dec. 07, 2023
Entity Registrant Name PFIZER INC
Entity Incorporation, State or Country Code DE
Entity File Number 1-3619
Entity Tax Identification Number 13-5315170
Entity Address, Address Line One 66 Hudson Boulevard East
Entity Address, City or Town New York,
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10001-2192
City Area Code 212
Local Phone Number 733-2323
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0000078003
Common Stock [Member]  
Entity Information [Line Items]  
Title of 12(b) Security Common Stock, $.05 par value
Trading Symbol PFE
Security Exchange Name NYSE
Notes Due 2027, 1.000% [Member]  
Entity Information [Line Items]  
Title of 12(b) Security 1.000% Notes due 2027
Trading Symbol PFE27
Security Exchange Name NYSE
XML 9 pfe-20231207_htm.xml IDEA: XBRL DOCUMENT 0000078003 2023-12-07 2023-12-07 0000078003 us-gaap:CommonStockMember 2023-12-07 2023-12-07 0000078003 pfe:NotesDue20271.000Member 2023-12-07 2023-12-07 0000078003 false 8-K 8-K 2023-12-07 2023-12-07 PFIZER INC PFIZER INC DE 1-3619 13-5315170 66 Hudson Boulevard East 10001-2192 New York, NY 212 733-2323 false false false false Common Stock, $.05 par value PFE NYSE 1.000% Notes due 2027 PFE27 NYSE false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

(/ !? M&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " !JA(Q799!YDAD! #/ P $P M @ $4$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" !> %% ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 3 22 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.pfizer.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports pfe-20231207.htm pfe-20231207.xsd pfe-20231207_def.xml pfe-20231207_lab.xml pfe-20231207_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "pfe-20231207.htm": { "nsprefix": "pfe", "nsuri": "http://www.pfizer.com/20231207", "dts": { "inline": { "local": [ "pfe-20231207.htm" ] }, "schema": { "local": [ "pfe-20231207.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "pfe-20231207_def.xml" ] }, "labelLink": { "local": [ "pfe-20231207_lab.xml" ] }, "presentationLink": { "local": [ "pfe-20231207_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 28 }, "report": { "R1": { "role": "http://www.pfizer.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "dei:DocumentType", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20231207.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "dei:DocumentType", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "pfe-20231207.htm", "first": true, "unique": true } } }, "tag": { "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "pfe_NotesDue20271.000Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pfizer.com/20231207", "localname": "NotesDue20271.000Member", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Due 2027, 1.000% [Member]", "label": "Notes Due 2027, 1.000% [Member]", "documentation": "Notes Due 2027, 1.000% [Member]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.pfizer.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0000078003-23-000118-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000078003-23-000118-xbrl.zip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end